Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Rhea-AI Summary

Immuron (Nasdaq:IMRN) reported first-half fiscal 2026 revenue of AUD$4.2 million for the six months ended December 31, 2025, a 5% increase year-over-year driven by Travelan sales in Australia and the U.S. Australian revenue rose 13% to AUD$3.3 million and U.S. revenue rose 17% to AUD$0.9 million; Canadian revenue declined due to distributor inventory dynamics.

The firm launched ProIBS in December 2025 in Australia and continues to invest in its polyclonal antibody platform and clinical-stage pipeline. Emerging Growth Research maintained a Buy-Extended rating and a $3.50 12-month price target, citing current product revenue, early commercial traction, and clinical potential while noting reliance on external capital to fund development.

Positive

• Australian revenue +13% YoY to AUD$3.3M
• U.S. revenue +17% YoY to AUD$0.9M

Negative

• Company remains dependent on external capital to fund clinical development
• Canadian revenue declined due to distributor-level inventory dynamics

Argus Jan 22 session

+1.42% close to close Open Argus

Details

News Market Reaction – IMRN

On Jan 22, the day this news came out, IMRN closed 1.42% above the previous close.

Data tracked by StockTitan Argus for the Jan 22 session.

Key Figures

H1 FY26 revenue: AUD$4.2 million Australia revenue: AUD$3.3 million U.S. revenue: AUD$0.9 million +5 more

H1 FY26 revenue

AUD$4.2 million

Six months ended December 31, 2025; 5% YoY increase

Australia revenue

AUD$3.3 million

H1 FY26, 13% year-over-year growth

U.S. revenue

AUD$0.9 million

H1 FY26, 17% year-over-year growth

Q1 FY26 sales

AUD$2.0 million

Unaudited Q1 FY26, 34% YoY growth

Shares via ATM

55,100,920 shares

Issued under ATM facility Oct–Dec 2025

ATM facility size

US$15 million

Form F-3 and ATM prospectus over three years

ATM extension

US$2,847,954

Additional approximate aggregate offering price

Current share price

$0.983

Pre-news price, 0.61% change over 24h

Historical Context

5 past events · Latest: Dec 03

5 events

1. Dec 03

   DoD award & trial

   24h Move

   -10.9%

   DoD-funded award and clinical trial timing update for Travelan-based products.

2. Nov 05

   IND approval

   24h Move

   -12.7%

   FDA IND approval enabling Phase 2 trial of IMM-529 in CDI patients.

3. Oct 31

   Clinical update

   24h Move

   -5.9%

   Updates on IMM-529 review status and Travelan P2TD trial timing change.

4. Oct 13

   Sales update

   24h Move

   +0.5%

   Q1 FY26 sales growth with strong Australia and U.S. Travelan performance.

5. Oct 08

   IND submission

   24h Move

   +2.7%

   Submission of IND for IMM-529 with outlined Phase 2 CDI trial plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ev/revenue, ads, at-the-market (atm) funding facility, form f-3, +1 more

5 terms

ev/revenue financial

"The $3.50 price target is based on a peer-group EV/Revenue valuation methodology"

EV/Revenue is a valuation ratio that compares a company’s total market value (including debt and cash) to its annual sales. Investors use it to judge how much they are paying for each dollar of revenue, which is helpful when profits vary or are negative — like comparing how much you’d pay for different shops based on their yearly receipts rather than their recent profit. Lower values often suggest cheaper relative valuation, higher values imply pricier expectations.

ads financial

"adjusted for its ADS structure."

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

at-the-market (atm) funding facility financial

"to ratify prior share issues made under its at-the-market (ATM) funding facility."

An at-the-market (ATM) funding facility is an arrangement that lets a company sell newly issued shares directly into the open market, bit by bit, at prevailing market prices through a broker. For investors it matters because it provides the company with flexible, often quicker access to cash but increases the number of shares outstanding — like adding more slices to a pie — which can lower each existing share’s ownership and put downward pressure on the stock price if done frequently.

form f-3 regulatory

"The company previously filed a Form F-3 and ATM prospectus in the United States"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

atm prospectus regulatory

"filed a Form F-3 and ATM prospectus in the United States"

A prospectus for an "at-the-market" (ATM) offering explains a company’s plan to sell newly issued shares directly into the open market over time, at prevailing prices, through one or more broker-dealers. Investors should care because it creates a standing ability for the company to raise cash quickly and incrementally—like an open tab the company can draw on—which can dilute existing shareholders and affect share price and supply.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.50 following the Company's release of first-half fiscal year 2026 operating results.

The Flash Report notes that Immuron reported global revenue of AUD$4.2 million for the six months ended December 31, 2025, representing a 5% increase compared to the prior-year period. Sales growth was driven primarily by continued demand for Travelan^®, the Company's over-the-counter immune supplement, particularly in Australia and the United States.

By geography, Australian revenue increased 13% year-over-year to AUD$3.3 million, while U.S. revenue rose 17% to AUD$0.9 million. Canadian revenue declined during the period, reflecting distributor-level inventory dynamics. Emerging Growth Research attributes overall performance to a combination of digital and in-store marketing initiatives and increased international travel activity.

The report also highlights the December 2025 launch of ProIBS^®, Immuron's new digestive health product, which management believes may support incremental revenue contribution over time as distribution expands in the Australian market.

Beyond commercial operations, the Flash Update reiterates Immuron's broader investment profile, including its polyclonal antibody technology platform and clinical-stage pipeline targeting infectious diseases of the gastrointestinal tract. The analyst notes that while revenue from commercial products partially offsets operating expenses, Immuron remains dependent on external capital to support ongoing clinical development.

According to Emerging Growth Research, the maintained Buy-Extended rating reflects the Company's combination of existing product revenue, early commercial traction in key markets, and longer-term clinical development potential, balanced against typical biotechnology risks related to funding, clinical outcomes, and execution.

The $3.50 price target is based on a peer-group EV/Revenue valuation methodology applied to Immuron's reported revenue, adjusted for its ADS structure.

For a copy of the full initiation report, please visit:

https://emerginggrowth.com/wp-content/uploads/2026/01/Immuron-Flash-Report-2026-01-22.pdf

or

https://www.EmergingGrowth.com/profile/imrn/ (on the right side of the page as you scroll down)

About Immuron Limited
Founded in 1994 and headquartered in Melbourne, Australia, Immuron Limited (Nasdaq:IMRN) is a commercial and clinical-stage biopharmaceutical company developing oral polyclonal antibody products for the treatment and prevention of gastrointestinal infectious diseases. Immuron's marketed products include Travelan^® and Protectyn^®, with additional candidates in clinical development targeting indications such as C. difficile infection and traveler's diarrhea.

About Emerging Growth Research
Emerging Growth Research is an independent research firm focused on providing institutional-style equity research coverage on emerging public companies. Emerging Growth Research distributes its reports through EmergingGrowth.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding Immuron Limited's business, financial performance, product development, and market outlook. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements.

CONTACT: Research@EmergingGrowth.com

SOURCE: Immuron Limited

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did Immuron (IMRN) report for the six months ended December 31, 2025?

Immuron reported AUD$4.2 million in global revenue for the six months ended December 31, 2025.

Why did Immuron (IMRN) maintain a $3.50 price target on January 22, 2026?

Emerging Growth Research maintained the $3.50 12-month target using a peer EV/Revenue valuation adjusted for the ADS structure.

How did Immuron's geographic sales perform in H1 FY2026 for IMRN?

Australian sales were AUD$3.3M (+13% YoY), U.S. sales were AUD$0.9M (+17% YoY), and Canadian revenue declined.

When did Immuron (IMRN) launch ProIBS and where?

Immuron launched ProIBS in December 2025 with initial distribution in the Australian market.

What are the main risks highlighted for Immuron (IMRN)?

Analyst risk factors include typical biotech execution and funding risks, plus reliance on external capital to support clinical programs.

Does Immuron's current revenue cover operating expenses for IMRN?

The report notes commercial product revenue partially offsets operating expenses, but external funding is still required.